Anti-CD20 ADC Composition for Relapsed DLBCL Response Improvement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) have unsatisfactory response rates and survival outcomes, with only 26-30% objective response rate and median OS of 5.9-6.3 months, necessitating the development of more effective drugs.
Innovation Solution
The use of an anti-CD20 antibody drug conjugate (ADC) with a drug-antibody ratio (DAR) of 4.2 ± 0.3 to 4.2 ± 1, administered in liquid or freeze-dried preparations, targeting NHL patients, particularly DLBCL, with specific excipients and buffers to enhance efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional R-CHOP regimen is used for treating NHL, then treatment is available and accessible, but objective response rate is low (26-30%) and median overall survival is short (5.9-6.3 months)
Solution Approach 1:
The patent changes the fundamental parameter of the treatment agent from conventional chemotherapy (R-CHOP regimen) to antibody-drug conjugates (ADCs) targeting CD20. This parameter change enables achieving objective response rates of 44.8-58.6% and disease control rates of 71.4-89.7%, significantly improving both response rate and survival outcomes for relapsed or refractory NHL patients
Solution Approach 2:
The patent employs composite therapeutic agents combining monoclonal antibodies (rituximab or biosimilars) with cytotoxic drugs through conjugation. This composite approach creates antibody-drug conjugates that simultaneously provide targeted delivery and potent cytotoxicity, resolving the contradiction between treatment accessibility and efficacy by offering a unified therapeutic modality that outperforms conventional separate chemotherapy agents
2Reliability
If high-dose chemotherapy and autologous hematopoietic stem cell transplantation is used, then disease cure is achieved, but only half of relapsed and refractory patients are suitable due to advanced age and comorbidities
Solution Approach 1:
The patent employs a more accessible and tolerable treatment approach using antibody-drug conjugates that can be administered to a broader patient population including those with advanced age and comorbidities who are not suitable for intensive ASCT. The ADC therapy provides effective disease control and response rates (44.8-58.6% ORR) without requiring the harsh conditions of high-dose chemotherapy and stem cell transplantation, making the treatment adaptable to more patients
Solution Approach 2:
The patent changes the treatment parameter from intensive ASCT (suitable for only 50% of patients) to ADC therapy with optimized drug-antibody ratios (DAR 4.2±0.3 to 4.2±1). This parameter change enables effective treatment across diverse patient populations including elderly and comorbid patients, improving both suitability and efficacy simultaneously
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-CD20 ADC demonstrates an objective response rate of 44.8-58.6% and disease control rate of 71.4-89.7%, showing significant clinical efficacy and safety in treating R/R NHL, especially DLBCL, with improved outcomes for non-GCB subtype, high LDH levels, elderly patients, and advanced clinical phases.
Implementation Method 1
anti-CD20 antibody drug conjugate (ADC)... targeting NHL patients, particularly DLBCL
Implementation Method 2
The anti-CD20 ADC demonstrates an objective response rate of 44.8-58.6% and disease control rate of 71.4-89.7%, showing significant clinical efficacy
Data Source
AI summary
The present disclosure discloses a use of anti-CD20 ADC in the preparation of a drug for treating NHL, and the drug has excellent clinical efficacy and safety in treating a R/R NHL patient after receiving at least two standard treatments.